Pacific Biosciences Of Stock Buy Hold or Sell Recommendation
| PACB Stock | USD 1.56 0.05 3.11% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Pacific Biosciences of is 'Strong Sell'. Macroaxis provides Pacific Biosciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PACB positions.
Check out Pacific Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Pacific and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Pacific |
Execute Pacific Biosciences Buy or Sell Advice
The Pacific recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Pacific Biosciences of. Macroaxis does not own or have any residual interests in Pacific Biosciences of or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Pacific Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Pacific Biosciences Trading Alerts and Improvement Suggestions
| Pacific Biosciences generated a negative expected return over the last 90 days | |
| Pacific Biosciences has high historical volatility and very poor performance | |
| Pacific Biosciences may become a speculative penny stock | |
| Pacific Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 200.52 M. Net Loss for the year was (306.74 M) with profit before overhead, payroll, taxes, and interest of 54.23 M. | |
| Pacific Biosciences of currently holds about 834.34 M in cash with (259.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pacific Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors |
Pacific Biosciences Returns Distribution Density
The distribution of Pacific Biosciences' historical returns is an attempt to chart the uncertainty of Pacific Biosciences' future price movements. The chart of the probability distribution of Pacific Biosciences daily returns describes the distribution of returns around its average expected value. We use Pacific Biosciences of price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Pacific Biosciences returns is essential to provide solid investment advice for Pacific Biosciences.
| Mean Return | -0.54 | Value At Risk | -9.69 | Potential Upside | 8.52 | Standard Deviation | 5.69 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Pacific Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Pacific Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Pacific Biosciences or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Pacific Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Pacific stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.58 | |
β | Beta against Dow Jones | 0.28 | |
σ | Overall volatility | 5.71 | |
Ir | Information ratio | -0.11 |
Pacific Biosciences Volatility Alert
Pacific Biosciences of exhibits very low volatility with skewness of 0.06 and kurtosis of -0.16. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pacific Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pacific Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Pacific Biosciences Fundamentals Vs Peers
Comparing Pacific Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Pacific Biosciences' direct or indirect competition across all of the common fundamentals between Pacific Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Pacific Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Pacific Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Pacific Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Pacific Biosciences to competition |
Note: Acquisition by Ordonez Kathy of 32179 shares of Pacific Biosciences at 1.65 subject to Rule 16b-3 [view details]
Pacific Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Pacific . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Pacific Biosciences Buy or Sell Advice
When is the right time to buy or sell Pacific Biosciences of? Buying financial instruments such as Pacific Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Pacific Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corona Opportunity Thematic Idea Now
Corona Opportunity
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Pacific Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.